Search CDIOW
Cardio Diagnostics Holdings, Inc.
Nasdaq, Nasdaq · CIK 1870144
Last close0.01
Daily change+0.00 (16.28%)
10 Years gain-60.32%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
CDIOW · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
37.7Momentum
0.0Acceleration
35.8Confidence
66.0Annual Revenue5
Quarterly Revenue15
Annual CFO5
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth17.3 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet6.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators0.0 / 5
Signals
ROIC expansionROIC improved by 7.9244 percentage points.
Warnings
Operating margin compression · MEDIUMOperating margin compressed by 6991.3651 percentage points.
Heavy share dilution · HIGHDiluted share count increased 75.517%.
Low interest coverage · HIGHInterest coverage is -454.0573x.
Key Metrics
Revenue Growth TTM-7.7%OK
Revenue CAGR 3Y149.89%OK
Gross Margin100%OK
Operating Margin-36,327.06%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-56.07%OK
Incremental Operating Margin 3Yn/aNOT_MEANINGFUL
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y75.52%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $14,825.00 | $14,825.00 | -$6.48M | -$5.73M | -$5.91M | 100% | -43,737.46% | -39,893.09% | -61.97% | 1.75M |
| 2025 FY Dec 31, 2024 | $34,890.00 | $34,890.00 | -$8.37M | -$4.99M | -$5.21M | 100% | -23,977.86% | -14,926.54% | -105.61% | 896,424 |
| 2024 FY Dec 31, 2023 | $17,065.00 | $17,065.00 | -$7.24M | -$5.67M | -$6.25M | 100% | -42,440.43% | -36,612% | -157.62% | 12.69M |
| 2023 FY Dec 31, 2022 | $950.00 | $950.00 | -$4.55M | -$5.09M | n/a | 100% | -478,784.32% | n/a | -133.83% | 3.09M |
| 2022 FY Dec 31, 2021 | $901.00 | $901.00 | -$620,448.00 | -$585,291.00 | n/a | 100% | -68,862.15% | n/a | n/a | 1.16M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $18,370.00 | sum latest 4 fiscal quarters Revenue | OK | 0001079973-26-001016, 0001079973-25-001686 |
| Revenue Growth TTM | -7.7% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001079973-26-001016, 0001079973-25-001686 |
| Revenue CAGR 3Y | 149.89% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001553350-26-000023 |
| Revenue CAGR 5Y | n/a | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | INSUFFICIENT_HISTORY | 0001553350-26-000023 |
| Gross Profit CAGR 3Y | 149.89% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001553350-26-000023 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001079973-26-001016, 0001079973-25-001686 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 100% | Gross Profit / Revenue | OK | 0001079973-26-001016, 0001079973-25-001686 |
| Operating Margin | -36,327.06% | Operating Income / Revenue | OK | 0001079973-26-001016, 0001079973-25-001686 |
| ROIC | -56.07% | NOPAT / Average Invested Capital | OK | 0001079973-26-001016, 0001079973-25-001686 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001079973-26-001016 |
| Interest Coverage | -454.06x | Operating Income / abs(Interest Expense) | OK | derived |
| Current Ratio | 17.15x | Current Assets / Current Liabilities | OK | derived |
| Revenue per Diluted Share | $0.01 | Revenue / Diluted Shares | OK | 0001079973-26-001016, 0001079973-25-001686 |